Johanna Andersson-Assarsson

Dr. Johanna Andersson-Assarsson

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2014 in JAMA
Verified
Journal Article
Closed access
PDF file
LSLars Sjöström
Lars Sjöström
MPMarkku Peltonen
Markku Peltonen
PJPeter Jacobson
Peter Jacobson
SASofie Ahlin
Sofie Ahlin
JAJohanna Andersson-Assarsson
Johanna Andersson-Assarsson
LCLena M. S. Carlsson
Lena M. S. Carlsson
Research from JAMA — Association of Bariatric Surgery With Long-term Remission of Type 2 Diabetes and With Microvascular and Macrovascular Complications

30 March 2014 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MFMario Falchi
Mario Falchi
JMJulia Sarah El-Sayed Moustafa
Julia Sarah El-Sayed Moustafa
PTPetros Takousis
Petros Takousis
FPFrancesco Pesce
Francesco Pesce
ABAmélie Bonnefond
Amélie Bonnefond
PFPhilippe Froguel
Philippe Froguel

1 May 2017 in Gynecologic Oncology
Verified
Journal Article
Closed access
ÅAÅsa Anveden
Åsa Anveden
MTMagdalena Taube
Magdalena Taube
MPMarkku Peltonen
Markku Peltonen
PJPeter Jacobson
Peter Jacobson
JAJohanna Andersson-Assarsson
Johanna Andersson-Assarsson
LCLena M.S. Carlsson
Lena M.S. Carlsson

1 April 2017 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Open access
LCLena M S Carlsson
Lena M S Carlsson
KSKajsa Sjöholm
Kajsa Sjöholm
CKCecilia Karlsson
Cecilia Karlsson
PJPeter Jacobson
Peter Jacobson
JAJohanna Andersson-Assarsson
Johanna Andersson-Assarsson
MPMarkku Peltonen
Markku Peltonen
Bariatric surgery is associated with remission of diabetes and prevention of diabetic complications in patients with obesity and type 2 diabetes. Long-term effects of bariatric surgery on microvascular complications in patients with prediabetes are unknown. The aim of this study was to examine the effects of bariatric surgery on incidence of microvascular complications in patients with obesity stratified by baseline glycaemic status. Patients were recruited to the Swedish Obese Subjects (SOS) study between Sept 1, 1987, and Jan 31, 2001. Inclusion criteria were age 37-60 years and BMI of 34 kg/m2 or greater in men and 38 kg/m2 or greater in women. Exclusion criteria were identical in surgery and control groups and designed to exclude patients not suitable for surgery. The surgery group (n=2010) underwent gastric bypass (265 [13%]), gastric banding (376 [19%]), or vertical-banded gastroplasty (1369 [68%]). Participants in the control group (n=2037) received usual care. Bodyweight was measured and questionnaires were completed at baseline and at 0·5 years, 1 year, 2 years, 3 years, 4 years, 6 years, 8 years, 10 years, 15 years, and 20 years. Biochemical variables were measured at baseline and at 2 years, 10 years, and 15 years. We categorised participants into subgroups on the basis of baseline glycaemic status (normal [fasting blood glucose concentration <5·0 mmol/L], prediabetes [5·0-6·0 mmol/L], screen-detected diabetes [≥6·1 mmol/L at baseline visit without previous diagnosis], and established diabetes [diagnosis of diabetes before study inclusion]). We obtained data about first incidence of microvascular disease from nationwide registers and about diabetes incidence at study visits at 2 years, 10 years, and 15 years. We did the main analysis by intention to treat, and subgroup analyses after stratification by baseline glycaemic status and by diabetes status at the 15 year follow-up. The SOS study is registered with ClinicalTrials.gov, NCT01479452. 4032 of the 4047 participants in the SOS study were included in this analysis. We excluded four patients with suspected type 1 diabetes, and 11 patients with unknown glycaemic status at baseline. At baseline, 2838 patients had normal blood glucose, 591 had prediabetes, 246 had screen-detected diabetes, and 357 had established diabetes. Median follow-up was 19 years (IQR 16-21). We identified 374 incident cases of microvascular disease in the control group and 224 in the surgery group (hazard ratio [HR] 0·56, 95% CI 0·48-0·66; p<0·0001). Interaction between baseline glycaemic status and effect of treatment on incidence of microvascular disease was significant (p=0·0003). Unadjusted HRs were lowest in the subgroup with prediabetes (0·18, 95% CI 0·11-0·30), followed by subgroups with screen-detected diabetes (0·39, 0·24-0·65), established diabetes (0·54, 0·40-0·72), and normoglycaemia (0·63, 0·48-0·81). Surgery was associated with reduced incidence of microvascular events in people with prediabetes regardless of whether they developed diabetes during follow-up. Bariatric surgery was associated with reduced risk of microvascular complications in all subgroups, but the greatest relative risk reduction was observed in patients with prediabetes at baseline. Our results suggest that prediabetes should be treated aggressively to prevent future microvascular events, and effective non-surgical treatments need to be developed for this purpose. US National Institutes of Health, Swedish Research Council, Sahlgrenska University Hospital Regional Agreement on Medical Education and Research, and Swedish Diabetes Foundation.

1 February 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
INIntawat Nookaew
Intawat Nookaew
PSPer-Arne Svensson
Per-Arne Svensson
PJPeter Jacobson
Peter Jacobson
MJMargareta Jernås
Margareta Jernås
MTMagdalena Taube
Magdalena Taube
LCLena M. S. Carlsson
Lena M. S. Carlsson
Context: Men and women differ in body fat distribution and adipose tissue metabolism as well as in obesity comorbidities and their response to obesity treatment. Objective: The objective of the study was a search for sex differences in adipose tissue function. Design and Setting: This was an exploratory study performed at a university hospital. Participants and Main Outcome Measures: Resting metabolic rate (RMR), body composition, and sc adipose tissue genome-wide expression were measured in the SOS Sib Pair study (n = 732). Results: The relative contribution of fat mass to RMR and the metabolic rate per kilogram adipose tissue was higher in women than in men (P value for sex by fat mass interaction = .0019). Women had increased expression of genes involved in mitochondrial function, here referred to as a mitochondrial gene signature. Analysis of liver, muscle, and blood showed that the pronounced mitochondrial gene signature in women was specific for adipose tissue. Brown adipocytes are dense in mitochondria, and the expression of the brown adipocyte marker uncoupling protein 1 was 5-fold higher in women compared with men in the SOS Sib Pair Study (P = 7.43 × 10−7), and this was confirmed in a cross-sectional, population-based study (n = 83, 6-fold higher in women, P = .00256). Conclusions: The increased expression of the brown adipocyte marker uncoupling protein 1 in women indicates that the higher relative contribution of the fat mass to RMR in women is in part explained by an increased number of brown adipocytes.

1 April 2019 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
SHStephan Hjorth
Stephan Hjorth
INIngmar Näslund
Ingmar Näslund
JAJohanna Andersson-Assarsson
Johanna Andersson-Assarsson
PSPer-Arne Svensson
Per-Arne Svensson
PJPeter Jacobson
Peter Jacobson
LCLena M. S. Carlsson
Lena M. S. Carlsson
The global prevalence of obesity has risen dramatically in recent decades. Worldwide, the number of people who are overweight or have obesity climbed from 857 million in 1980 to 2.1 billion in 2013.1 Because of the multiple, well-established health risks accompanying excess weight and the absence of efficacious nonsurgical weight loss treatments, bariatric surgery has become increasingly common, especially in patients with severe obesity.2 Over the years, several different surgical techniques have also been developed and refined.3 However, revisional surgery as a result of the shortcomings of the initial bariatric procedure appears to be frequent and sometimes includes reversal to normal anatomy.4-6 Previous literature typically covers short-term to intermediate-term (<5 years) follow-up of smaller cohorts, often at a single center (eg, Brethauer et al7). Incidence figures also vary widely (inter alia, with respect to type of primary surgical procedure, cohort size, and duration of follow-up). Main indications listed include technical, complication-associated, and weight-associated factors.